Shanu Modi News Today

New drugs called antibody-drug conjugates help patients with cancers that used to be beyond treatment

Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.

Trastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression.

Treatment with fam-trastuzumab deruxtecan-nxki led to sustained improvements in overall survival and progression-free survival vs physician’s choice of treatment in patients with previously treated HER2-low metastatic breast cancer, irrespective of hormone receptor status.

Learn how MSK's expertise in metastatic breast cancer helped a mother celebrate a long-awaited milestone with her family.

Novel data with trastuzumab deruxtecan, sacituzumab govitecan, and ribociclib have demonstrated an influx of overall survival advantages compared with standard-of-care regimens across breast cancer patient subsets, including HER2-positive, hormone receptor–positive, and triple-negative disease.

Here are the biggest inventions and advances of 2022, from scientists, doctors, and health care advocates who reached incredible milestones.

Practice-changing therapy for HER2-low breast cancer, potential for some women to skip surgery

During a highly-anticipated “Cancer Breakthroughs” session at ASTRO2022, incoming ASTRO President Jeff Michalski, MD, MBA, FASTRO, moderated the presentation of significant findings from representatives of ASCO and AAPM.

Progression-free survival in newly recognized subtype doubled with trastuzumab deruxtecan